The discovery and subsequent clinical introduction of antibiotics is one of the most important game-changers in the history of medicine [1]. These drugs have saved millions of lives from infections that would previously have been fatal, and later, they allowed for the introduction of surgical interventions, organ transplantation, care of premature infants, and cancer chemotherapy [2]. Nevertheless, the therapy of bacterial infections is becoming less and less straightforward due to the emergence of multidrug resistance (MDR) in these pathogens [3]. Direct consequences of antibiotic resistance include delays in the onset of the appropriate (effective) antimicrobial therapy, the need to use older, more toxic antibiotics (e.g., colistin) with a disadvantageous side-effect profile, longer hospital stays, and an increasing burden on the healthcare infrastructure; overall, a decrease in the quality-of-life (QoL) and an increase in the mortality rate of the affected patients [4,5]. To highlight the severity of the issue, several international declarations have been published to call governments around the globe to take action on antimicrobial resistance [6,7,8,9].
Since the 1980s, pharmaceutical companies have slowly turned away from antimicrobial research and towards the drug therapy of chronic non-communicable diseases [10,11]. New antimicrobials are usually used as last-resort agents in a narrow patient population, resulting in smaller profits [12]. Additionally, drug companies are failing to keep up with the developments in global resistance levels; development of non-susceptibility to the novel antibiotics is inevitable, shortening the period of clinical usefulness of these drugs [13]. During the last years, a number of antibiotics have received marketing authorization from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (Table 1) [14,15,16].
Table 1.
Antibiotics recently approved by the Food and Drug Administration (FDA) and/or European Medicines Agency (EMA).
| Active Pharmaceutical Ingredient | Trade Name | Class/Comments |
|---|---|---|
| Doripenem | Doribax ™ (US) Finibax ™ (EU) |
Carbapenem |
| Ceftaroline fosamil | Teflaro ™ (US) Zinforo™ (EU) |
Cephalosporin |
| Ceftobiprole medocaril | Zevtera™(US) Mabelio™ (EU) |
Cephalosporin |
| Ceftolozane/tazobactam | Zerbaxa ™ (US/EU) | Combination antibiotic: cephalosporin/β-lactamase inhibitor |
| Ceftazidime/avibactam | Avycaz™ (US/EU) | Combination antibiotic: cephalosporin/β-lactamase inhibitor |
| Meropenem/vaborbactam | Vabomere™ (US) Carbavance™ (EU) |
Combination antibiotic: carbapenem/β-lactamase inhibitor |
| Imipenem/cilastatin/relebactam | Recarbrio ™ (US/EU) | Combination antibiotic: carbapenem/renal dehydropeptidase inhibitor/β-lactamase inhibitor |
| Telavancin | Vibativ™ (US) | Derivatives of either vancomycin or lipoglycopeptide |
| Dalbavancin | Dalvance™ (US) Xydalba™ (EU) |
Derivatives of either vancomycin or lipoglycopeptide |
| Oritavancin | Orbactiv™ (US/EU) | Derivatives of either vancomycin or lipoglycopeptide |
| Eravacycline | Xerava™ (US/EU) | Tetracycline derivatives |
| Sarecycline | Seysara™ (US) | Tetracycline derivatives |
| Omadacycline | Nuzyra™ (US) | Tetracycline derivatives |
| Bedaquiline, | Sirturo™ (US/EU) | Diarylquinoline (DARQ) |
| Tedizolid | Sivextro ™ (US/EU) | Oxazolidinone |
| Delafloxacin meglumine | Baxdela™ (US) | Fluoroquinolone |
| Plazomicin | Zemdri ™ (US) | Next-generation aminoglycoside (neoglycoside) |
| Lefamulin | Xenleta™ (US) | Pleuromutilin |
US: Trade name in the United States; EU: trade name in the member states of the European Union.
Although the number of newly marketed antibiotics and the current state of the antimicrobial pipeline offers hope (owing to government-funded research programs and public–private partnerships, generating incentive for pharmaceutical companies), there are several pathogens where providing appropriate therapy is still a major concern [10,11,12,13]. Based on their resistance levels and clinical significance, the so-called “ESKAPE” pathogens (Table 2) receive the utmost attention when it comes to the development of novel antimicrobials [17,18,19,20,21]. This was further highlighted after the World Health Organization declared these microorganisms as priority pathogens for pharmaceutical companies [22].
Table 2.
Current list of ESKAPE pathogens.
| Pathogens |
|---|
| Enterococcus faecium |
|
Staphylococcus aureus
(Stenotrophomonas maltophilia) |
|
Klebsiella pneumoniae
(Clostridioides difficile) |
| Acinetobacter spp. |
| Pseudomonas aeruginosa |
|
Enterobacter spp. (members of Enterobacterales) |
One of the main driving forces behind the development of antibacterial drug resistance is the misuse and overuse of these drugs, both in human medicine and in agriculture [1,2,3]. Thus, programs and interventions aiming at optimizing the use of antimicrobial drugs (such as implementation of policies and guidelines, drug utilization reports, point prevalence surveys, both locally and internationally), collectively termed “antimicrobial stewardship”, have received substantial attention [23]. Antimicrobial stewardship includes decisions like the selection of the dose and duration of the most appropriate antimicrobial(s) for the patient with limited or no side effects, ensuring minimal impact on local resistance levels, ensuring their availability and efficacy for the future [24]. In addition, the implementation of rapid diagnostic techniques in clinical microbiology laboratories (diagnostic stewardship) to aid the choice of drug therapy is another emerging facet of antimicrobial stewardship [25]. This is also highlighted in scientific research; while in 2008, there were only n = 45 articles on this topic, in 2018, a nearly twenty-fold increase was observed (n = 804). To attain changes clinical practice, the appropriate attitude of healthcare professionals and their continuous professional development is of utmost importance [26,27].
Considering the importance of antibiotic resistance and its effects on the QoL of patients and on the state of healthcare infrastructures as a whole, it is our pleasure to co-edit the Special Issue in Antibiotics, termed “Antibiotic Resistance: From the Bench to Patients”. The Special Issue contains excellent quality research articles and comprehensive review papers on the epidemiology of various MDR pathogens worldwide, novel diagnostic and point-of-care (POCT) tests, interventional studies on antimicrobial drug utilization and pharmaco-epidemiological studies. In addition, the Special Issue welcomes reports on the knowledge, attitude, and practice of healthcare professionals (nurses, doctors, pharmacists, etc.) and patients regarding antibiotics and antibiotic resistance.
Acknowledgments
Márió Gajdács was supported by the National Youth Excellence Scholarship (Grant Number NTP-NTFÖ-18-C-0225) and the ESCMID Mentorship and Observership Programme. Fernando Albericio was partially supported by Fundació La Marató (Grant 201835-31).
Author Contributions
M.G. and F.A. equally contributed in writing the article.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- 1.Gaynes R. The Discovery of Penicillin—New Insights after More Than 75 Years of Clinical Use. Emerg. Infect. Dis. 2017;23:849–853. doi: 10.3201/eid2305.161556. [DOI] [Google Scholar]
- 2.Shallcross L.J., Howard S.J., Fowler T., Davies S.C. Tackling the threat of antimicrobial resistance: From policy to sustainable action. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2015;370:20140082. doi: 10.1098/rstb.2014.0082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Laxminarayan R., Duse A., Wattal C., Zaidi A.K.M., Wertheim H.F.L., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., et al. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 2013;13:1057–1098. doi: 10.1016/S1473-3099(13)70318-9. [DOI] [PubMed] [Google Scholar]
- 4.Cassini A., Högberg D.L., Plachouras D., Quattrocchi A., Hoxha A., Simonsen G.N., Colomb-Cotinat M., Kretzschmar M.E., Devleesschauwer B., Cecchini M., et al. Burden of the AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2019;19:55–56. doi: 10.1016/S1473-3099(18)30605-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Gajdács M., Urbán E. Comparative Epidemiology and Resistance Trends of Proteae in Urinary Tract Infections of Inpatients and Outpatients: A 10-Year Retrospective Study. Antibiotics. 2019;8:91. doi: 10.3390/antibiotics8030091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. [(accessed on 18 August 2019)]; Available online: https://amr-review.org/sites/default/files/AMRReviewPaper-Tacklingacrisisforthehealthandwealthofnations_1.pdf.
- 7.World Health Organisation . Antimicrobial Resistance: Global Report on Surveillance. WHO; Geneva, Switzerland: 2014. [(accessed on 18 August 2019)]. pp. 1–256. Available online: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1. [Google Scholar]
- 8.ECDC/EMEA Joint Technical Report (2009). The Bacterial Challenge: Time to React. [(accessed on 18 August 2019)]; Available online: http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf.
- 9.CDC Antibiotic/Antimicrobial Resistance (AR/AMR) [(accessed on 18 August 2019)]; Available online: https://www.cdc.gov/drugresistance/biggest_threats.html.
- 10.Darrow J.J., Kesselheim A.S. Drug development and FDA approval, 1938–2013. N. Engl. J. Med. 2014;370:e39. doi: 10.1056/NEJMp1402114. [DOI] [PubMed] [Google Scholar]
- 11.Gajdács M. The concept of an ideal antibiotic: Implications for drug design. Molecules. 2019;24:892. doi: 10.3390/molecules24050892. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Infectious Diseases Society of America The 10 x ’20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 2010;50:1081–1083. doi: 10.1086/652237. [DOI] [PubMed] [Google Scholar]
- 13.Projan S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 2003;6:427–430. doi: 10.1016/j.mib.2003.08.003. [DOI] [PubMed] [Google Scholar]
- 14.de la Torre B., Albericio F. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2019;24:809. doi: 10.3390/molecules24040809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Karaiskos I., Lagou S., Pontikis K., Rapti V., Poulakou G. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front. Public Health. 2019 doi: 10.3389/fpubh.2019.00151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Abbas M., Paul M., Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin. Microbiol. Infect. 2017;23:697–703. doi: 10.1016/j.cmi.2017.06.010. [DOI] [PubMed] [Google Scholar]
- 17.Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J. Infect. Dis. 2009;197:1079–1081. doi: 10.1086/533452. [DOI] [PubMed] [Google Scholar]
- 18.Gajdács M. The Continuing Threat of Methicillin-Resistant Staphylococcus aureus. Antibiotics. 2019;8:52. doi: 10.3390/antibiotics8020052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Sheu C.C., Chang Y.T., Lin S.Y., Chen Y.H., Hsueh P.R. Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Front. Microbiol. 2019;10:80. doi: 10.3389/fmicb.2019.00080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Gajdács M., Urbán E. Epidemiological Trends and Resistance Associated with Stenotrophomonas maltophilia Bacteremia: A 10-Year Retrospective Cohort Study in a Tertiary-Care Hospital in Hungary. Diseases. 2019;7:41. doi: 10.3390/diseases7020041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ahmed M.O., Baptiste K.E. Vancomycin-Resistant Enterococci: A Review of Antimicrobial Resistance Mechanisms and Perspectives of Human and Animal Health. Microb. Drug Resist. 2018;24:590–606. doi: 10.1089/mdr.2017.0147. [DOI] [PubMed] [Google Scholar]
- 22.World Health Organization . Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. WHO; Geneva, Switzerland: 2017. [(accessed on 18 August 2019)]. pp. 1–7. Available online: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. [Google Scholar]
- 23.Ha D.R., Haste N.M., Gluckstein D.P. The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use. Am. J. Lifestyle Med. 2017 doi: 10.1177/1559827617700824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Dyar O.J., Huttner B., Schouten J., Pulcini C. What is antimicrobial stewardship? Clin. Microbiol. Infect. 2017;23:793–798. doi: 10.1016/j.cmi.2017.08.026. [DOI] [PubMed] [Google Scholar]
- 25.Morgan D.J., Malani P., Diekema D.J. Diagnostic stewardship-leveraging the laboratory to improve antimicrobial use. JAMA. 2017;318:607–608. doi: 10.1001/jama.2017.8531. [DOI] [PubMed] [Google Scholar]
- 26.Gajdács M., Paulik E., Szabó A. [The opinions of community pharmacists related to antibiotic use and resistance] (article in Hungarian) Acta Pharm. Hung. 2018;88:249–252. [Google Scholar]
- 27.Dyar O.J., Hills H., Seitz L.T., Perry A., Ashiru-Oredope D. Assessing the Knowledge, Attitudes and Behaviors of Human and Animal Health Students towards Antibiotic Use and Resistance: A Pilot Cross-Sectional Study in the UK. Antibiotics (Basel) 2018 doi: 10.3390/antibiotics7010010. [DOI] [PMC free article] [PubMed] [Google Scholar]